• 1
    Okosieme OE,Parkes AB,Premawardhana LD,Evans C,Lazarus JH. Thyroglobulin: current aspects of its role in autoimmune thyroid disease and thyroid cancer. Minerva Med. 2003; 94: 319330.
  • 2
    Mazzaferri EL,Robbins RJ,Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003; 88: 14331441.
  • 3
    Pacini F,Agate L,Elisei R, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab. 2001; 86: 40924097.
  • 4
    Ma C,Xie J,Kuang A. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results? J Nucl Med. 2005; 46: 11641170.
  • 5
    Whitley RJ,Ain KB. Thyroglobulin: a specific serum marker for the management of thyroid carcinoma. Clin Lab Med. 2004; 24: 2947.
  • 6
    Verburg FA,Lips CJ,Lentjes EG,de Klerk JM. Detection of circulating Tg-mRNA in the follow-up of papillary and follicular thyroid cancer: how useful is it? Br J Cancer. 2004; 91: 200204.
  • 7
    Jones JJ,Brunaud L,Dowd CF,Duh QY,Morita E,Clark OH. Accuracy of selective venous sampling for intact parathyroid hormone in difficult patients with recurrent or persistent hyperparathyroidism. Surgery. 2002; 132: 944950; discussion, 950–951.
  • 8
    Fugazzola L,Pinchera A,Luchetti F, et al. Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers. 1994; 9: 2124.
  • 9
    Abdelmoumene N,Schlumberger M,Gardet P, et al. Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma. Br J Cancer. 1994; 69: 11411144.
  • 10
    Tan YY,Oqilvie JB,Triponez F, et al. Selective use of adrenal venous sampling in the lateralization of aldosterone-producing adenomas. World J Surg. 2006; 30: 879885; discussion, 886–887.
  • 11
    Brandle M,Pfammatter T,Spinas GA,Lehmann R,Schmid C. Assessment of selective arterial calcium stimulation and hepatic venous sampling to localize insulin-secreting tumours. Clin Endocrinol (Oxf). 2001; 55: 357362.
  • 12
    Medina-Franco H,Herrera MF,Lopez G, et al. Persistent hypercalcitoninemia in patients with medullary thyroid cancer: a therapeutic approach based on selective venous sampling for calcitonin. Rev Invest Clin. 2001; 53: 212217.
  • 13
    Doppman JL,Jensen RT. Localization of gastroenteropancreatic tumours by angiography. Ital J Gastroenterol Hepatol. 1999; 31(suppl 2): S163S166.
  • 14
    Dhillo WS,Jayasena CN,Jackson JE, et al. Localization of gastrinomas by selective intra-arterial calcium injection in patients on proton pump inhibitor or H2 receptor antagonist therapy. Eur J Gastroenterol Hepatol. 2005; 17: 429433.
  • 15
    Hocevar M,Auersperg M,Stanovnik L. The dynamics of serum thyroglobulin elimination from the body after thyroid surgery. Eur J Surg Oncol. 1997; 23: 208210.
  • 16
    Valenta LJ,Eisenberg H,Ascher MS,Elias AN. Response of thyroid hormones in peripheral and thyroid venous blood to TRH administration in man. Horm Res. 1983; 17: 7883.
  • 17
    Tegler L,Ericsson UB,Gillquist J,Lindvall R. Basal and thyrotropin-stimulated secretion rates of thyroglobulin from the human thyroid gland during surgery. Thyroid. 1993; 3: 213217.